WHO WE ARE
Alliance Foundation Trials, LLC (AFT) is a research organization that develops and conducts cancer clinical trials, working closely with pharmaceutical partners, research collaborators and the Alliance for Clinical Trials in Oncology scientific investigators and institutional member network. AFT seeks to fulfill the vision of the Alliance for Clinical Trials in Oncology to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.
Established in 2014 as a limited liability corporation, AFT is managed by the Alliance for Clinical Trials in Oncology Foundation, which is its sole member. The AFT operational structure and funding sources are separate from the Alliance clinical trials program funded by the National Cancer Institute (NCI).
Monica M. Bertagnolli, MD | President
An internationally renowned surgeon-scientist, Monica M. Bertagnolli, MD, is Chief of the Division of Surgical Oncology at Brigham and Women's Hospital and Professor of Surgery at Harvard Medical School. She is also Group Chair of the Alliance for Clinical Trials in Oncology, President of the Alliance for Clinical Trials in Oncology Foundation, and is currently serving as the 2018-2019 President of the American Society for Clinical Oncology.
Her innovative research has focused on gastrointestinal tumor biology, striving to develop patient-specific cancer prevention and treatment strategies. Dr. Bertagnolli specifically investigates the adenomatous polyposis coli (APC) gene function and its regulation of colorectal cancer. Her clinical practice is dedicated to patients with germline APC gene mutations.
Suzanne George, MD | Vice President
A leading medical oncologist and expert in sarcoma management and clinical investigation, Suzanne George, MD, is Clinical Director at the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School. She is also Group Vice-Chair of the Alliance for Clinical Trials in Oncology.
Her interests haves led her to develop and lead multiple clinical trials evaluating novel therapeutics for patients with advanced sarcomas and GIST, much of which has impacted the standard of care for patients with these diseases. She has also led one of the largest clinical multidisciplinary sarcoma teams, bringing together various specialists with the goal of optimizing patient care and outcomes.
Olwen Hahn, MD | Chief Scientific Officer
Olwen Hahn, MD, is Associate Professor of Medicine at the University of Chicago. As her clinical practice focuses on the diagnosis and treatment of breast cancer, she is also Principal Investigator and Director of the Central Protocol Operations Program at the Alliance for Clinical Trials in Oncology.
In addition, she serves as the primary investigator on multiple studies that examine the effectiveness of new drugs in breast cancer. She has authored numerous articles in scientific journals. Dr. Hahn has also been the recipient of the University of Chicago Distinguished Clinician Award, and is a Junior Faculty Scholar of the Bucksbaum Institute for Clinical Excellence.
Shira Dinner, MD | Northwestern University
David Kozono, MD, PhD | Dana-Farber Cancer Institute
Otto Metzger, MD | Dana-Farber Cancer Institute
Ardaman Shergill, MD | University of Chicago
Michael Tetzlaff, MD, PhD | MD Anderson Cancer Center
Anna Weiss, MD | Dana-Farber Cancer Institute